Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider?
Acamprosate
/ adverse effects
Alcohol Abstinence
Alcohol Deterrents
/ adverse effects
Alcoholism
/ drug therapy
Animals
Comorbidity
Disulfiram
/ adverse effects
Female
Fetal Alcohol Spectrum Disorders
/ prevention & control
Humans
Naltrexone
/ administration & dosage
Pregnancy
Pregnancy Complications
/ drug therapy
Pregnancy Outcome
/ epidemiology
Substance Withdrawal Syndrome
/ prevention & control
Journal
Drugs
ISSN: 1179-1950
Titre abrégé: Drugs
Pays: New Zealand
ID NLM: 7600076
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
accepted:
24
03
2021
pubmed:
9
4
2021
medline:
16
11
2021
entrez:
8
4
2021
Statut:
ppublish
Résumé
It is generally recommended that medications only be used in pregnancy where the potential harms to both the mother and foetus are outweighed by the potential benefits. Despite the known harms associated with alcohol consumption during pregnancy, the use of medication for the treatment of pregnant women with an alcohol use disorder (AUD) appears to be rare. This is likely due to the lack of available data regarding the safety of these medications in pregnancy. We reviewed the literature and weighed up the harms associated with alcohol use and AUD during pregnancy with the potential benefits of medications for AUD in pregnancy, including acamprosate, naltrexone and disulfiram. There is little published evidence to support the safety of medications for AUD in pregnancy. However, from the research available it is likely that only disulfiram has the potential to cause serious foetal harm. While further research is required, acamprosate and naltrexone do not appear to be associated with substantial risks of congenital malformations or other serious consequences. Given the potential risks associated with alcohol consumption during pregnancy, the use of acamprosate and naltrexone should be considered for the treatment of pregnant women with AUD based on the current evidence base, although more research is warranted.
Identifiants
pubmed: 33830479
doi: 10.1007/s40265-021-01509-x
pii: 10.1007/s40265-021-01509-x
doi:
Substances chimiques
Alcohol Deterrents
0
Naltrexone
5S6W795CQM
Acamprosate
N4K14YGM3J
Disulfiram
TR3MLJ1UAI
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
739-748Références
Krubiner CB, Faden RR. Pregnant women should not be categorised as a “vulnerable population” in biomedical research studies: ending a vicious cycle of “vulnerability.” J Med Ethics. 2017;43(10):664–5.
pubmed: 28716976
MIMS Online [Internet]. MIMS Australia Pty Ltd. 2020 [cited 08/Jan/2019]. https://www.mimsonline.com.au/Search/Search.aspx . Accessed 11 Mar 2021.
Blinick G, Jerez E, Wallach RC. Methadone maintenance, pregnancy, and progeny. JAMA. 1973;225(5):477–9.
pubmed: 4740334
Bro SP, Kjaersgaard MI, Parner ET, Sorensen MJ, Olsen J, Bech BH, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139–47.
pubmed: 25657597
pmcid: 4317061
McElhatton PR, Garbis HM, Eléfant E, Vial T, Bellemin B, Mastroiacovo P, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol. 1996;10(4):285–94.
pubmed: 8829251
Patel SI, Pennell PB. Management of epilepsy during pregnancy: an update. Ther Adv Neurol Disord. 2016;9(2):118–29.
pubmed: 27006699
NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. J Allergy Clin Immunol. 2005;115(1):34–46.
Kelty E, Tran DT, Lavin T, Preen DB, Hulse G, Havard A. Prevalence and safety of acamprosate use in pregnant alcohol dependent women in New South Wales, Australia. Addiction. 2019;114(2):206–15.
pubmed: 30152012
Lingford-Hughes AR, Welch S, Peters L, Nutt DJ. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol. 2012;26(7):899–952.
pubmed: 22628390
Thibaut F, Chagraoui A, Buckley L, Gressier F, Labad J, Lamy S, et al. WFSBP (*) and IAWMH (**) Guidelines for the treatment of alcohol use disorders in pregnant women. World J Biol Psychiatry. 2019;20(1):17–50.
pubmed: 30632868
Haber P, Lintzeris N, Proude E, Lopatko O. Guidelines for the treatment of alcohol problems. Canberra: Australian Government Department of Health and Ageing; 2009.
Aliyu MH, Wilson RE, Zoorob R, Chakrabarty S, Alio AP, Kirby RS, et al. Alcohol consumption during pregnancy and the risk of early stillbirth among singletons. Alcohol (Fayetteville, NY). 2008;42(5):369–74.
Sokol RJ, Miller SI, Reed G. Alcohol abuse during pregnancy: an epidemiologic study. Alcohol Clin Exp Res. 1980;4(2):135–45.
pubmed: 6990816
World Health Organisation. Global status report on alcohol and health 2018. Geneva: World Health Organisation; 2018.
Carson G, Cox LV, Crane J, Croteau P, Graves L, Kluka S, et al. Alcohol use and pregnancy consensus clinical guidelines. J ObstetGynaecol Can. 2010;32(8):S1–2.
Rolland B, Paille F, Gillet C, Rigaud A, Moirand R, Dano C, et al. Pharmacotherapy for alcohol dependence: the 2015 recommendations of the french alcohol society, issued in partnership with the european federation of addiction societies. CNS NeurosciTher. 2016;22(1):25–37.
Bailey BA, Sokol RJ. Pregnancy and alcohol use: evidence and recommendations for prenatal care. Clin Obstet Gynecol. 2008;51(2):436–44.
pubmed: 18463472
Popova S, Lange S, Probst C, Gmel G, Rehm J. Estimation of national, regional, and global prevalence of alcohol use during pregnancy and fetal alcohol syndrome: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(3):e290–9.
pubmed: 28089487
Mota N, Cox BJ, Enns MW, Calhoun L, Sareen J. The relationship between mental disorders, quality of life, and pregnancy: Findings from a nationally representative sample. J Affect Disord. 2008;109(3):300–4.
pubmed: 18191209
Edwards AC, Ohlsson H, Sundquist J, Sundquist K, Kendler KS. Protective effects of pregnancy on risk of alcohol use disorder. Am J Psychiatry. 2019;176(2):138–45.
pubmed: 30486670
Coyne KL, de Costa CM, Heazlewood RJ, Newman HC. Pregnancy characteristics of women giving birth to children with fetal alcohol syndrome in Far North Queensland. Aust N Z J Obstet Gynaecol. 2008;48(3):240–7.
pubmed: 18532953
Aliyu MH, Lynch ON, Nana PN, Alio AP, Wilson RE, Marty PJ, et al. Alcohol consumption during pregnancy and risk of placental abruption and placenta previa. Matern Child Health J. 2011;15(5):670–6.
pubmed: 20437196
Committee on Substance Abuse and Committee on Children With Disabilities. Fetal alcohol syndrome and alcohol-related neurodevelopmental disorders. Pediatrics. 2000;106(2):358–61.
Sokol RJ, Delaney-Black V, Nordstrom B. Fetal alcohol spectrum disorder. JAMA. 2003;290(22):2996–9.
pubmed: 14665662
Lange S, Probst C, Gmel G, Rehm J, Burd L, Popova S. Global prevalence of fetal alcohol spectrum disorder among children and youth: a systematic review and meta-analysis. JAMA Pediatr. 2017;171(10):948–56.
pubmed: 28828483
pmcid: 5710622
Centers for Disease Control and Prevention (CDC). Alcohol use and binge drinking among women of childbearing age—United States, 2006–2010. MMWR Morb Mortal Wkly Rep. 2012;61(28):534-8.
Greenmyer JR, Klug MG, Kambeitz C, Popova S, Burd L. A multicountry updated assessment of the economic impact of fetal alcohol spectrum disorder: costs for children and adults. J Addict Med. 2018;12(6):466–73.
pubmed: 30383615
May PA, Gossage JP. Maternal risk factors for fetal alcohol spectrum disorders: not as simple as it might seem. Alcohol Res Health J NatlInst Alcohol Abuse Alcoholism. 2011;34(1):15–26.
Kattimani S, Bharadwaj B. Clinical management of alcohol withdrawal: A systematic review. Ind Psychiatry J. 2013;22(2):100–8.
pubmed: 25013309
pmcid: 4085800
McKeon A, Frye MA, Delanty N. The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry. 2008;79(8):854–62.
pubmed: 17986499
O’Malley SS, O’Connor PG. Medications for unhealthy alcohol use: across the spectrum. Alcohol Res Health. 2011;33(4):300–12.
pubmed: 23580015
pmcid: 3860540
Rehm J, Rehm M, Alho H, Allamani A, Aubin H-J, Bühringer G, et al. Alcohol dependence treatment in the EU: a literature search and expert consultation about the availability and use of guidelines in all EU countries plus Iceland, Norway, and Switzerland. Int J Alcohol Drug Res. 2013;2(2):15.
Heilig M. Acamprosate: an alcoholism treatment that may not be what we thought. Neuropsychopharmacology. 2014;39(4):781–2.
pubmed: 24518272
pmcid: 3924516
Spanagel R, Pendyala G, Abarca C, Zghoul T, Sanchis-Segura C, Magnone MC, et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med. 2005;11(1):35–42.
pubmed: 15608650
Umhau JC, Momenan R, Schwandt ML, et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry. 2010;67(10):1069–77.
pubmed: 20921123
pmcid: 3583213
Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28(1):51–63.
pubmed: 14745302
Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;9:Cd004332.
Rosenthal RN, Gage A, Perhach JL, Goodman AM. Acamprosate: safety and tolerability in the treatment of alcohol dependence. J Addict Med. 2008;2(1):40–50.
pubmed: 21768971
Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. 1993;621(1):137–40.
pubmed: 7693299
Gonzales RA, Weiss F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci. 1998;18(24):10663–71.
pubmed: 9852601
pmcid: 6793337
Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;12:Cd001867.
Bolton M, Hodkinson A, Boda S, Mould A, Panagioti M, Rhodes S, et al. Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis. BMC Med. 2019;17(1):10.
pubmed: 30642329
pmcid: 6332608
Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. Arch Gen Psychiatry. 1997;54(12):1130–5.
pubmed: 9400350
Lindros KO, Stowell A, Pikkarainen P, Salaspuro M. The disulfiram (antabuse)-alcohol reaction in male alcoholics: its efficient management by 4-methylpyrazole. Alcoholism ClinExp Res. 1981;5(4):528–30.
Center for Substance Abuse T. SAMHSA/CSAT Treatment Improvement Protocols. Incorporating Alcohol Pharmacotherapies Into Medical Practice: A Review of the Literature. Rockville: Substance Abuse and Mental Health Services Administration (US); 2009.
Azrin NH, Sisson RW, Meyers R, Godley M. Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatry. 1982;13(2):105–12.
pubmed: 7130406
O’Farrell TJ, Allen JP, Litten RZ. Disulfiram (antabuse) contracts in treatment of alcoholism. NIDA Res Monogr. 1995;150:65–91.
pubmed: 8742773
Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS ONE. 2014;9(2):e87366.
pubmed: 24520330
pmcid: 3919718
Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B, et al. Disulfiram treatment of alcoholism. Br J Psychiatry. 1992;161:84–9.
pubmed: 1638335
Helzer JE, Pryzbeck TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol. 1988;49(3):219–24.
pubmed: 3374135
Jeanblanc J. Comorbidity between psychiatric diseases and alcohol use disorders: impact of adolescent alcohol consumption. Curr Addict Rep. 2015;2(4):293–301.
Batel P, Pessione F, MaÎTre C, Rueff B. Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction. 1995;90(7):977–80.
pubmed: 7663320
Hesselbrock MN, Segal B. Multiple substance dependence and course of alcoholism among Alaska native men and women AU—malcolm. Substance Use Misuse. 2006;41(5):729–41.
pubmed: 16603457
Pitel AL, Beaunieux H, Witkowski T, Vabret F, Guillery-Girard B, Quinette P, et al. Genuine episodic memory deficits and executive dysfunctions in alcoholic subjects early in abstinence. Alcoholism ClinExp Res. 2007;31(7):1169–78.
Anderson P, Cremona A, Paton A, Turner C, Wallace P. The risk of alcohol. Addiction. 1993;88(11):1493–508.
pubmed: 8286995
Ambrogne SJ. Struggling to reconnect: women’s perspectives on alcohol dependence, violence, and sexual function. J Am Psychiatr Nurses Assoc. 2009;14(6):421–8.
Tuchman E. Women and addiction: the importance of gender issues in substance abuse research. J Addict Dis. 2010;29(2):127–38.
pubmed: 20407972
Grant JD, Heath AC, Bucholz KK, Madden PA, Agrawal A, Statham DJ, et al. Spousal concordance for alcohol dependence: evidence for assortative mating or spousal interaction effects? Alcohol Clin Exp Res. 2007;31(5):717–28.
pubmed: 17378921
Agrawal A, Heath AC, Grant JD, Pergadia ML, Statham DJ, Bucholz KK, et al. Assortative mating for cigarette smoking and for alcohol consumption in female australian twins and their spouses. Behav Genet. 2006;36(4):553–66.
pubmed: 16710775
Furtwængler NAFF, de Visser RO. Lack of international consensus in low-risk drinking guidelines. Drug Alcohol Rev. 2013;32(1):11–8.
pubmed: 22672631
Monte R, Rabuñal R, Casariego E, López-Agreda H, Mateos A, Pértega S. Analysis of the factors determining survival of alcoholic withdrawal syndrome patients in a general hospital. Alcohol Alcohol. 2010;45(2):151–8.
pubmed: 20075027
Thomas JD, Riley EP. Fetal alcohol syndrome: does alcohol withdrawal play a role? Alcohol Health Res World. 1998;22(1):47–53.
pubmed: 15706733
pmcid: 6761815
DeVido J, Bogunovic O, Weiss RD. Alcohol use disorders in pregnancy. Harv Rev Psychiatry. 2015;23(2):112–21.
pubmed: 25747924
pmcid: 4530607
Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, Horvitz-Lennon M, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86–90.
pubmed: 29301420
Coles CD, Smith IE, Fernhoff PM, Falek A. Neonatal ethanol withdrawal: characteristics in clinically normal, nondysmorphic neonates. J Pediatr. 1984;105(3):445–51.
pubmed: 6470868
Schaff E, Moreno M, Foster K, Klug MG, Burd L. What do we know about prevalence and management of intoxicated women during labor and delivery? Glob Pediatric Health. 2019;6:2333794X19894799.
Bhat A, Hadley A. The management of alcohol withdrawal in pregnancy—case report, literature review and preliminary recommendations. Gen Hosp Psychiatry. 2015;37(3):273.e1-273.e3.
Shyken JM, Babbar S, Babbar S, Forinash A. Benzodiazepines in pregnancy. Clin Obstet Gynecol. 2019;62(1):156–67.
pubmed: 30628916
O’Connor MJ, Whaley SE. Brief intervention for alcohol use by pregnant women. Am J Public Health. 2007;97(2):252–8.
pubmed: 17194863
pmcid: 1781394
Chang G, Wilkins-Haug L, Berman S, Goetz MA. Brief intervention for alcohol use in pregnancy: a randomized trial. Addiction. 1999;94(10):1499–508.
pubmed: 10790902
Lui S, Terplan M, Smith EJ. Psychosocial interventions for women enrolled in alcohol treatment during pregnancy. Cochrane Database Syst Rev. 2008;3:CD006753.
WHO. Guidelines for the identification and management of substance use and substance use disorders in pregnancy. Geneva: World Health Organisation; 2014.
Adde-Michel C, Hennebert O, Laudenbach V, Marret S, Leroux P. Effect of acamprosate on neonatal excitotoxic cortical lesions in in utero alcohol-exposed hamsters. Neurosci Lett. 2005;374(2):109–12.
pubmed: 15644274
al Qatari M, Khan S, Harris B, Littleton J. Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol ClinExp Res. 2001;25(9):1276–83.
McLaughlin PJ, Tobias SW, Lang CM, Zagon IS. Chronic exposure to the opioid antagonist naltrexone during pregnancy: maternal and offspring effects. PhysiolBehav. 1997;62(3):501–8.
Zagon IS, McLaughlin PJ. Naltrexone modulates growth in infant rats. Life Sci. 1983;33(24):2449–54.
pubmed: 6316064
Farid WO, Lawrence AJ, Krstew EV, Tait RJ, Hulse GK, Dunlop SA. Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood. PLoS ONE. 2012;7(12):e52812.
pubmed: 23300784
pmcid: 3530485
Salgo MP, Oster G. Fetal resorption induced by disulfiram in rats. J Reprod Fertil. 1974;39(2):375–7.
pubmed: 4413461
Harding AJ, Edwards MJ. Retardation of prenatal brain growth of guinea pigs by disulfiram1. CongenitAnom. 1993;33(3):197–202.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.
Hulse GK, O’Neil G, Arnold-Reed DE. Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. Int J Gynaecol Obstet. 2004;85(2):170–1.
pubmed: 15099783
Kelty E, Hulse G. A retrospective cohort study of obstetric outcomes in opioid-dependent women treated with implant naltrexone, oral methadone or sublingual buprenorphine, and non-dependent controls. Drugs. 2017;77(11):1199–210.
pubmed: 28536980
Kelty E, Hulse G. A retrospective cohort study of birth outcomes in neonates exposed to naltrexone in utero: a comparison with methadone-, buprenorphine- and non-opioid-exposed neonates. Drugs. 2017;77(11):1211–9.
pubmed: 28536981
Wachman EM, Saia K, Miller M, Valle E, Shrestha H, Carter G, et al. Naltrexone treatment for pregnant women with opioid use disorder compared with matched buprenorphine control subjects. Clin Ther. 2019.
Towers CV, Katz E, Weitz B, Visconti K. Use of naltrexone in treating opioid use disorder in pregnancy. Am J Obstet Gynecol. 2020;222.
Dehaene P, Titran M, Dubois D. Pierre Robin syndrome and heart malformations in a newborn infant. The role of disulfiram during pregnancy? PresseMedicale (Paris, France). 1984;13(22):1394–5.
Reitnauer PJ, Callanan NP, Farber RA, Aylsworth AS. Prenatal exposure to disulfiram implicated in the cause of malformations in discordant monozygotic twins. Teratology. 1997;56(6):358–62.
pubmed: 9485545
Helmbrecht GD, Hoskins IA. First trimester disulfiram exposure: report of two cases. Am J Perinatol. 1993;10(1):5–7.
pubmed: 8442800
Gardner RJ, Clarkson JE. A malformed child whose previously alcoholic mother had taken disulfiram. N Z Med J. 1981;93(680):184–6.
pubmed: 6941103
Nora A, Nora J, Blu J. Limb-reduction anomalies in infants born to disulfiram-treated alcoholic mothers. Lancet. 1977;310(8039):664.
Krans EE, Cochran G, Bogen DL. Caring for opioid-dependent pregnant women: prenatal and postpartum care considerations. ClinObstetGynecol. 2015;58(2):370–9.
Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat. 2008;35(3):245–59.
pubmed: 18248941
pmcid: 2633026
Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction. 2014;109(8):1320–33.
pubmed: 24661272
Burns L, Mattick RP, Cooke M. The use of record linkage to examine illicit drug use in pregnancy. Addiction. 2006;101(6):873–82.
pubmed: 16696631
Maeda A, Bateman BT, Clancy CR, Creanga AA, Leffert LR. Opioid abuse and dependence during pregnancy: temporal trends and obstetrical outcomes. Anesthesiology. 2014;121(6):1158–65.
pubmed: 25405293
Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369(9566):1047–53.
pubmed: 17382831
Gambling L, McArdle HJ. Iron, copper and fetal development. Proc Nutr Soc. 2004;63(4):553–62.
pubmed: 15831127
Campbell MA, Fantel AG. Teratogenicity of acetaldehyde invitro: relevance to the fatal alcohol syndrome. Life Sci. 1983;32(23):2641–7.
pubmed: 6855459
Rhee DL, Sang MA, Soon SK, Gyu SR, Seung JK, Ji HS, et al. Neurotoxic effects of alcohol and acetaldehyde during embryonic development. J Toxicol Environ Health Part A. 2005;68(23–24):2147–62.
Pechnick RN, Manalo CM, Lacayo LM, Vit JP, Bholat Y, Spivak I, et al. Acamprosate attenuates cue-induced reinstatement of nicotine-seeking behavior in rats. Behav Pharmacol. 2011;22(3):222–7.
pubmed: 21522053
Kiefer F, Wiedemann K. Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol. 2004;39(6):542–7.
pubmed: 15456690
Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol ClinExp Res. 1998;22(3):573–9.
Morley KC, Logge W, Pearson S-A, Baillie A, Haber PS. National trends in alcohol pharmacotherapy: Findings from an Australian claims database. Drug Alcohol Depend. 2016;166:254–7.
pubmed: 27394934